Funded by a European Union grant under the Horizon 2020 health program, the consortium convenes 39 industrial and academic partners from Europe, the United States and Africa to develop innovative concepts for both prophylactic and therapeutic HIV vaccines. The effort is led by Yves Lévy, CEO of the French Institute of Health and Medical Research (INSERM), and Giuseppe Pantaleo, Executive Director of the Swiss Vaccine Research Institute at Lausanne University Hospital (CHUV). The consortium grant is supplemented with additional funding from the Swiss Government for the Swiss project partners.
IAVI will provide product development support to help the consortium’s vaccine candidates to advance through clinical assessment. The IAVI Human Immunology Laboratory, a partnership with Imperial College London, will help assess immune responses induced in EHVA’s clinical trials. IAVI’s European regional office in Amsterdam will help coordinate the consortium’s communications activities.
“We commend the European Commission for its critical support of the effort to develop safe, effective and broadly accessible AIDS vaccines,” said Thomas Hassell, IAVI Vice President, Vaccine Development. “We are very happy to support this important research program and look forward to collaborating with the consortium’s wide array of eminent researchers.”
Click here to read INSERM’s EHVA announcement.
IAVI also supports the Horizon 2020 European AIDS Vaccine Initiative consortium announced in November; click here to read more.